African Journal of Microbiology Research Vol. 6(2), pp. 251-256, 16 January, 2012
Available online at http://www.academicjournals.org/AJMR
ISSN 1996-0808 ©2012 Academic Journals
DOI: 10.5897/AJMR11.1036

Full Length Research Paper

Effect of *Astragalus mongholicus* injection liquid on the immunity function in children with congenital heart disease (CHD) after undergoing cardiopulmonary bypass surgery

Li Tong[1], She Shaoyi[2], Zhang Ge[3], and Huang Weizhe[4]*

[1]Department of Paediatrics, The First Affiliated Hospital of Shantou University Medical College, Shantou, PR China.
[2]Department of Urology, The First Affiliated Hospital of Shantou University Medical College, Shantou, PR China.
[3]Departments of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Shatin, NT, Hong Kong.
[4]Department of Cardiac Pulmonary Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, PR China.

Accepted 20 October, 2011

The effect of the administration of *Astragalus mongholicus* (AM) injection liquid on the immunity function in children with congenital heart disease (CHD) after undergoing cardiopulmonary bypass surgery was examined. Sixty-two children with congenital heart disease were randomly assigned to group B (untreated control, n=21) or C (n=19) and D (n=22) (2, or 4 mg/kg daily astragalus membranac injection liquid intravenously for 6 days after anesthesia induction after undergoing cardiopulmonary bypass surgery). Another 23 patients (group A) served as pre-operational control. Results showed that *Astragalus mongholicus* injection liquid can enhance serum immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM), tumor necrosis factor alpha (TNF- α), soluble vascular cellular adhesion molecules (sVCAM-1) and soluble intercellular adhesion molecule 1 (sICAM). It can be concluded that astragalus membranac injection liquid can improve the immunity function in children with CHD after undergoing cardiopulmonary bypass surgery.

Key words: *Astragalus mongholicus* injection liquid, cardiopulmonary bypass surgery, CHD, sVCAM-1.

INTRODUCTION

The traditional Chinese herb can be categorized by different functions and *Astragalus mongholicus* belongs to the kind which can reinforce the functions of organisms. Both pharmacology and clinical practices have demonstrated that Astragalus membranaceus exhibited hepatoprotective, immunostimulating, cardiotonic and antiaging activities (Zee-Cheng, 1992; Sinclair, 1998; Cui et al., 2003; Cho and Leung, 2007a, b). The main constituents of the root of Astragalus membranaceus include flavonoids, polysaccharides, saponins, amino acids, and trace elements (Shao et al., 2004; Cho, 2010). There is no recent clinical evidence to guide dosages of *Astragalus* products. However, typical recommendations are 2–6 g of the powdered root (Monograph, 2003). In traditional medicine, AM has been used for the treatment of general weakness, chronic illness, and to increase overall vitality. Different peripheral effects such as improved sensitivity to insulin (Lin et al., 2000), immune modulation, antiviral activity, antineoplastic activity, and enhancement of cardio-vascular functions have been described (Monograph, 2003). The protection of cardiovascular function might be explained in terms of protection against membrane lipid peroxidation (Chen et al., 1995; Wang et al., 1996; Toda and Shirataki, 1999). Bioactive components isolated from *Astragalus mongholicus* are processed into a new drug, *Astragalus mongholicus* injection liquid, by modern technology in china.

*Corresponding author. E-mail: huangweizhe733@sina.com.

Table 1. Effect of *Astragalus membranac* injection liquid on IgA, IgG and IgM in children with CHD.

Group	IgA (g/L)	IgG (g/L)	IgM (g/L)
A	10.65±0.96	3.86±0.33	2.11±0.17
B	6.06±0.57 [b]	1.43±0.12 [b]	1.08±0.11 [b]
C	8.57±0.93 [c]	2.98±0.19 [c]	1.79±0.19 [c]
D	9.96±0.79 [d]	3.64±0.25 [d]	2.12±0.32 [d]

[b] $P<0.01$, compared with group A; [c] $P<0.05$, [d] $P<0.01$, compared with group B.

Long-term survival in children and adults with congenital heart disease (CHD) has improved markedly with advances in medical and surgical therapies. Despite these advances, a growing number of patients with complex CHD will ultimately require heart transplantation (HT) for end-stage heart failure. CHD has been identified as a risk factor for 1-year outcome after transplantation (Lamour et al., 2009), but studies identifying specific risk factors for poor outcome after transplantation for CHD in the combined adult and pediatric population have not been performed.

In this study, we evaluated effect of Astragalus mongholicus injection liquid on immunity function of children with CHD after undergoing cardiopulmonary bypass surgery.

METHODS

Subject and experiment design

Astragalus mongholicus injection liquid was purchased from a local drug shop (Shantou, China). In September 2010, Eighty-three children, ages 8 to 14 years, who were diagnosed as congenital heart disease; Liver, kidney and heart failure, tumour, severe generalized infection, and autoimmune diseases were excluded. Sixty-two children with congenital heart disease were randomly assigned to group B (untreated control, n=21) or C (n=19) and D (n=22) (2, or 4 mg/kg daily astragalus membranac injection liquid intravenously for 6 days after anesthesia induction after undergoing cardiopulmonary bypass surgery). We have obtained consent from the patients involved in this study. The Cardiopulmonary bypass machine used in the study was a Sarns 8000 nonpulsatile roller occlusive pump (Terumo, Belgium). The same Cardiopulmonary bypass circuit set-up was used for all patients. This consisted of a closed system with a soft shell reservoir and a Hilite 1000 oxygenator (Medos, Germany), which is used for flows up to 1 l/min. Patients received cold crystalloid cardioplegia (St Thomas' Solution with a K^+ concentration of 20 mmol/l) administered by the anaesthetist at a dose of 30 ml/kg after cross clamping, which then passed through the pump. All patients received one dose of cardioplegia except for four patients undergoing cavo-pulmonary shunts that did not receive any. Another 23 patients (group A) served as preoperation control. After the 7th day, central venous blood samples were taken. Plasma immunoglobulin, TNF- α, sICAM-1, and sVCAM-1 were measured.

Biochemical analysis

IgA, IgG, IgM, TNF-α, sICAM-1, and sVCAM-1 were measured using ELISA kits.

Statistical analysis

Data were analyzed by SPSS (version 11) software. Continuous variables are presented as mean ± standard deviation and comparisons were made by means of analysis of variance. Statistical significance was assumed if $p < 0.05$.

RESULTS AND DISCUSSION

A congenital heart defect (CHD) is a defect in the structure of the heart and great vessels which is present at birth. Many types of heart defects exist, most of which either obstruct blood flow in the heart or vessels near it, or cause blood to flow through the heart in an abnormal pattern (Miller et al., 2011). Other defects, such as long QT syndrome, affect the heart's rhythm. Heart defects are among the most common birth defects and are the leading cause of birth defect-related deaths. The success of cardiac surgery in childhood has produced a large population of adults with congenital heart disease. These adults present a unique challenge for the cardiology community. With more than 30 different forms of congenital heart disease, it can be difficult for adult patients to find cardiologists familiar with their particular anatomy and problems (Verheugt et al., 2008).

It is now recognised that many children with recurrent chest infections have abnormalities in their ability to produce specific antibodies to common respiratory pathogens such as the Strep. pneumoniae or H. influenzae which is commonly isolated from their sputum. If an antibody deficiency is suspected, total serum levels of IgG, IgM, IgA and IgE should be measured. As the normal ranges of these proteins change during childhood, the measured values must be compared to the age-appropriate normal values, ideally from the same laboratory (Couriel, 2002).

In the present experiment, Table 1 shows the effect of astragalus membranac injection liquid on immunity function in children with CHD. Plasma IgA, IgG and IgM levels in children with CHD (group B) were markedly lower than those in preoperation group (A). The astragalus membranac injection liquid had considerable elevating effect on the decreased IgA, IgG and IgM levels(group C and D) when compared with the group B (Figure 1).

Tumor necrosis factor (TNF or TNF-a/cachectin) is a proinflammatory cytokine that acts as a mediator of host



Figure 1. Effect of astragalus membranac injection liquid on IgA, IgG and IgM in children with CHD. [b] *P*<0.01, compared with group A; [c] *P*<0.05, [d] *P*<0.01, compared with group B

Table 2. Effect of astragalus membranac injection liquid on TNF- α in children with CHD.

Group	TNF- α
A	19.58±2.43
B	11.75±1.98 [b]
C	15.08±1.69 [d]
D	18.59±1.66 [d]

[b] *P*<0.01, compared with group A; [d] *P*<0.01, compared with group B.

defense against both neoplasia and infection and is principally expressed in macrophages (Beutler and Cerami, 1988; Ziegler, 1988; Waage et al., 1987; Old, 1987), where its secretion may be increased 10,000-fold after exposure to bacterial endotoxin (LPS) (Beutler et al., 1986). Along with numerous beneficial roles in immune regulation, TNF has been implicated in the pathogenesis of both acute and chronic inflammatory disease (Beutler and Cerami. 1986), and therefore it is of great interest to dissect the molecular mechanisms of TNF gene expression. The observation that TNF-α is elevated in individuals with advanced heart failure (HF) prompted several high-profile clinical trials investigating whether TNF inhibitors could be used to treat HF.

Table 2 shows the effect of astragalus membranac injection liquid on TNF-α in children with CHD. Plasma TNF-α level in children with CHD (group B) was markedly lower than that in preoperation group (A). The astragalus membranac injection liquid had considerable elevating effect on the decreased TNF-α level (group C and D) when compared with the group B (Figure 2).

Soluble cell adhesion molecules (sCAMs) are a class of cell adhesion molecule (CAMs - cell surface binding proteins) that may represent important biomarkers for inflammatory processes involving activation or damage to cells such as platelets and the endothelium (Hwang et al., 2005). In the present study, sICAM-1 in blood of children with CHD was investigated. Plasma sICAM-1 in children with CHD (group B) were found to be significantly lower than the preoperation group (A). Treatment of the astragalus membranac injection liquid after cardiopulmonary bypass surgery increased the plasma sICAM-1 in group C and D as compared to the children with CHD (group B) (Table 3 and Figure 3).



Figure 2. Effect of astragalus membranac injection liquid on TNF- α in children with CHD. [b] *P*<0.01, compared with group A; [d] *P*<0.01, compared with group B.

Table 3. Effect of astragalus membranac injection liquid on sICAM-1 in children with CHD.

Group	sICAM-1
A	395.1±36.9
B	254.3±27.7 [b]
C	298.4±22.7 [d]
D	376.3±40.5 [d]

[b] *P*<0.01, compared with group A; [d] *P*<0.01, compared with group B.



Figure 3. Effect of astragalus membranac injection liquid on sICAM-1 in children with CHD. [b] *P*<0.01, compared with group A; [d] *P*<0.01, compared with group B.

Table 4. Effect of astragalus membranac injection liquid on sVCAM-1 in children with CHD.

Group	sVCAM-1
A	984.9±100.8
B	684.2±57.85 [b]
C	842.7±94.2 [d]
D	965.4±103.7 [d]

[b] $P<0.01$, compared with group A; [d] $P<0.01$, compared with group B.



Figure 4. Effect of astragalus membranac injection liquid on sVCAM-1 in children with CHD.[b] $P<0.01$, compared with group A; [d] $P<0.01$, compared with group B

Endothelial cells release multiple inflammatory mediators and express various adhesion molecules such as intercellular and vascular cellular adhesion molecules (ICAM-1, VCAM-1), P- and E-selectins (Khan and Chakrabarti, 2007). Endothelial vascular adhesion molecule-1 (VCAM-1) is a critical component of the leukocyte–endothelial adhesion cascade, and its strict temporal and spatial regulation makes it an ideal target for imaging and therapy. The counter-receptors VCAM-1 are overexpressed on the activated endothelial cell surface. They undergo shedding and their soluble forms, sVCAM-1 are detectable in the serum and considered to be markers of endothelial cell activity or injury (Springer, 1990; Kuryliszyn Moskal et al., 2005). Thus, endothelial cell injury and activation participate in the pathogenesis of both PHT (via obliterative vasculopathy) (Seibold et al., 2001) and ILD (via direct and indirect roles in inducing fibroblast activation that leads ultimately to fibrosis) (Cerinic et al., 2003).

sVCAM-1 in blood of children with CHD was investigated. Plasma sVCAM-1 in children with CHD (group B) were found to be significantly lower than the preoperation group (A). Treatment of the astragalus membranac injection liquid after cardiopulmonary bypass surgery increased the plasma sVCAM-1 in group C and D as compared to the children with CHD (group B) (Table 4 and Figure 4).

Conclusion

Astragalus membranac injection liquid can improve the immunity function in children with CHD after undergoing cardiopulmonary bypass surgery.

REFERENCES

Beutler B, Cerami A (1988). Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem., 57:505.
Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A (1986). Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Sciences, 232:978.
Beutler B, Cerami A (1986). Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature, 320:584.
Cerinic MM, Valentini G, Sorano GG, D'Angelo S, Cuomo G, Fenu L,

Generini S, Cinotti S, Morfini M, Pignone A, Guiducci S, Del Rosso A, Kalfin R, Das D, Marongiu F (2003). Blood coagulation, fibrinolysis and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum, 32: 285–295.

Cho WC, Leung KN (2007a). *In vitro* and *in vivo* immunomodulating and immunorestorative effects of *Astragalus membranaceus*. J. Ethnopharmacol., 113:132-41.

Cho WC, Leung KN (2007b). In vitro and in vivo anti-tumor effects of *Astragalus membranaceus*. Cancer Lett., 252:43-54.

Cho WC (2010). *Astragalus*, *Astragalus membranaceus* (Fisch.) Bge. In Awaad AS, Singh VK, Govil JN (eds): Recent Progress in Medicinal Plants, Volume 28, Drug Plants II. Houston, USA: Studium Press, LLC: 31-45.

Cui R, He JC, Wang B, Zhang F, Chen GY, Yin S, Shen H (2003), Suppressive effect of *Astragalus membranaceus* Bunge on chemical hepatocarcinogenesis in rats. Cancer Chemother. Pharmacol., 51: 75–80.

Chen LX, Liao JZ, Guo WQ (1995). Effects of *Astragalus membranaceus* on left ventricular function and oxygen free radical in acute myocardial infarction patients and mechanisms of its cardiotonic action. Zhongguo Zhong Xi Yi Jie He Ha Zhi, 15: 141–143.

Couriel J (2002). Assessment of the child with recurrent chest infections. Br. Med. Bull., 61 (1): 115-132.

Old LJ (1987). Tumor necrosis factor: another chapter in the long history of endotoxin. Nat., 330:602.

Hwang Y-S, Tsai W-C, Lu Y-H, Lin C-C, Tsai K-Y (2005). Effects of angiotensin II-receptor blockers on soluble cell adhesion molecule levels in uncomplicated systemic hypertension: An observational, controlled pilot study in Taiwanese adults. Curr. Therap. Res., 66: 181-194.

Khan ZA, Chakrabarti S (2007). Cellular signaling and potential new treatment targets in diabetic retinopathy. Exp. Diabetes Res., 2007: 31867.

Kuryliszyn MA, Klimiuk PA, Sierakowski S (2005). Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin. Rheumatol., 24: 111–116.

Lamour JM, Kanter KR, Naftel DC, Chrisant MR, Morrow WR, Clemson BS, Kirklin JK (2009). The Effect of Age, Diagnosis, and Previous Surgery in Children and Adults Undergoing Heart Transplantation for Congenital Heart Disease. J. Am. Coll. Cardiol., 54:160-165.

Lin LZ, He XG, Lindenmaier M, Nolan G, Yang J, Cleary M, Qiu SX, Cordell GA (2000), Liquid chromatography–electrospray ionization mass spectrometry study of the flavonoids of the roots of Astragalus mongholicus and A. membranaceus. J. Chromatogr. A., 876: 87–95.

Miller A, Riehle-Colarusso T, Alverson CJ, Frías JL, Correa A (2011). Congenital Heart Defects and Major Structural Noncardiac Anomalies, Atlanta, Georgia, 1968 to 2005. J. Pediatrics., 159: 70-78.e2.

Monograph (2003), *Astragalus membranaceus*. Altern. Med. Rev., 8, pp. 72–77.

Seibold JR, Ruddy SS, Harris ED, Sledge CB, Kelley WN (2001). Editors, Kelley's textbook of rheumatology, (6th ed.), W.B. Saunders Company, Philadelphia pp. 1211–1240.

Shao BM, Xu W, Dai H, Yu P, Li Z, Gao XM (2004), A study on the immune receptors for polysaccharides from the roots of *Astragalus membranaceus*, a Chinese medicinal herb. Biochem Biophys. Res. Commun., 320: 1103–1111.

Sinclair S (1998). Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. Altern. Med. Rev., 3: 338–344.

Springer TA (1990). Adhesion receptors of the immune system. Nature., 346: 425–434.

Toda S, Shirataki Y (1999). Inhibitory effects of Astragali radix, a crude drug in oriental medicines, on lipid peroxidation and protein oxidative modifications by copper. J. Ethnopharmacol., 68: 331–333.

Verheugt CL, Uiterwaal CSPM, Grobbee DE, Mulder BJM (2008). Long-term prognosis of congenital heart defects: A systematic review. Int. J. Cardiol., 131: 25-32.

Wang D, Shen W, Tian Y, Sun Z, Jiang C, Yuan S (1996). Protective effect of active components extracted from radix Astragali on human erythrocyte membrane damages caused by reactive oxygen species,. Zhongguo Zhong Yao Za Zhi, 21: 746–748 763.

Zee-Cheng RK (1992). Shi-quan-da-bu-tang (ten significant tonic decoction), SQT. A potent Chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. Methods Findings Exp. Clin. Pharmacol., 14: 725–736.

Ziegler EJ (1988). Tumor necrosis factor in humans. N. Engl. J. Med., 318:1533.